Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Jun 09, 2021 1:21pm
140 Views
Post# 33355809

RE:RE:status of things

RE:RE:status of thingsThanks RC.  As i understand the Immusafe JV structure, Test 1 is 50-50 rev split and Test 2 would be 80-20 in favor of PMN due to use of PMN reagents.

Regarding US market, I suspect they have been talking w/ FDA given some of the statements on the covidimmunitypassport website about US samples being sent for processing to a specific approved lab in WA state.  

But perhaps there is some reciprocity agreement between FDA and HC that they are leveraging as well.

Regarding competition, I think PMN is in a pretty good spot still, given those recent application templates posted by FDA, as well as the recent FDA announcement you shared.

At the end of the day, if we enter a JV with someone, we share the success as well as the blame for any misteps. 

I am hopeful that the curent regulatory climate will be amenable to speedy approvals.  The world needs answers on these questions asap.  
<< Previous
Bullboard Posts
Next >>